BH vs LEG

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong recent price performance (+110.4% over 1Y), the stock trades at an extremely high P/E of 217.27 versus negative Forward P/E, signaling earnings deterioration. Profitability metrics are concerning, with a mere 0.54% net margin and 0.35% ROE, well below sector averages. While the balance sheet shows a healthy current ratio and low Price/Book of 0.50, these are overshadowed by unsustainable valuation and weak earnings momentum.

LEG presents as a classic deep-value play with a stable Piotroski F-Score of 4/9 and a current price ($11.13) trading significantly below its Graham Number ($16.94). While valuation metrics like the P/E (6.59) and P/S (0.37) are exceptionally low, these are offset by a concerning -11.20% YoY revenue decline and a total lack of earnings beats over the last four quarters. The stock is caught between strong balance sheet liquidity (Current Ratio 2.25) and a severe long-term price collapse (-73% over 5 years), suggesting a 'value trap' risk despite the low entry point.